Efficacy of Taurolidine Containing Lock Solution for Prevention of Central Venous Catheter Infection in ICU Patients

Tanta University

Status: Completed

Conditions: Prevention; Lock Solution; Taurolidine; Intensive Care Unit; Central Venous Catheter Infection

Treatments: Drug: Taurolidine-citrate-heparin; Drug: Tigecycline and heparin; Drug: Saline

Study type: Interventional

Funder types: Other

Identifiers

NCT07366372

36264MD73/4/23

Details and patient eligibility

About

This study aimed to assess effectiveness of a taurolidine based lock solution in preventing the infections of central venous catheter (CVC) in intensive care unit (ICU) cases.

Full description

The central venous catheter (CVC) is highly frequent in the intensive care unit (ICU), with an average use rate between 32% and 80% among adult ICU patients. The utilization of CVC in ICUs has escalated over the past decade, accompanied by a corresponding increase in problems related to their usage.

Taurolidine is a nontoxic substance having antibacterial impacts counter to mutually gram-positive and -negative bacteria, additionally to fungus. It decreases biofilm development and doesn't develop resistance to antibiotics, since it serves as an antiseptic rather than an antibiotic Consequently, it may function as a locking mechanism.

Enrollment: 120 patients

Sex: All

Ages: 21+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 21 years.
• Both genders.
• Patients admitted to the intensive care unit (ICU) requiring central venous catheter insertion.

Exclusion criteria

• Cases with active infections, hemorrhage or bleeding disorders, infections within insertion place.
• History of allergy to taurolidine, tigecycline, heparin, and citrate.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

120 participants in 3 patient groups, including a placebo group

Group I

Placebo Comparator group

Description:

Central venous catheters (CVCs) were locked with 2ml saline as a control group.

Treatment:

Drug: Saline

Group II

Experimental group

Description:

Central venous catheters (CVCs) were locked with 2ml of a solution comprising tigecycline 5mg/ml and heparin 500 IU/ml.

Treatment:

Drug: Tigecycline and heparin

Group III

Experimental group

Description:

Central venous catheters (CVCs) were locked with 2ml of a solution containing taurolidine-citrate-heparin (1.35% taurolidine, 4% citrate, and 500 IU/ml heparin).

Treatment:

Drug: Taurolidine-citrate-heparin